Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria

Journal of Infectious Diseases

Volumn 205, Issue 9, 2012, Pages 1456-1463

  Yadava, Anjali ^a   Nurmukhambetova, Saule ^a   Pichugin, Alexander V ^a   Lumsden, Joanne M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; UNCLASSIFIED DRUG; VIVAX MALARIA PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DNA SEQUENCE; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE TEST; MALARIA; MALARIA CONTROL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE LOAD; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

AFRICA; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; CROSS PROTECTION; EPITOPES; FEMALE; IMMUNIZATION; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS, DNA; SPECIES SPECIFICITY; SPOROZOITES;

EID: 84861541468     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis220     Document Type: Article

References (31)

1. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010; 6:90-6.
2. Yadava A, Sattabongkot J, Washington MA, et al. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 2007; 75:1177-85.
3. Herrera S, Fernandez OL, Vera O, et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with Montanide ISA 720 or Montanide ISA 51. Am J Trop Med Hyg 2011; 84:12-20.
4. Herrera S, Corradin G, Arevalo-Herrera M. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 2007; 23:122-8.
5. Regules JA, Cummings JF, Ockenhouse CF. The RTS, S vaccine candidate for malaria. Expert Rev Vaccines 2011; 10:589-99.
6. Aide P, Aponte JJ, Renom M, et al. Safety, immunogenicity and duration of protection of the RTS, S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One 2010; 5:e13838.
7. Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol 2004; 34:991-6.
8. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, doubleblind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009; 200:337-46.
9. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003; 13:387-98.
10. Mazier D, Mellouk S, Beaudoin RL, et al. Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro. Science 1986; 231:156-9.
11. Nudelman S, Renia L, Charoenvit Y, et al. Dual action of anti-sporozoite antibodies in vitro. J Immunol 1989; 143:996-1000.
12. Bongfen SE, Ntsama PM, Offner S, et al. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 2009; 27:328-35.
13. Bilsborough J, Baumgart K, Bathurst I, Barr P, Good MF. Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites. Acta Trop 1997; 65:59-80.
14. Ying P, Shakibaei M, Patankar MS, et al. The malaria circumsporozoite protein: interaction of the conserved regions I and II-plus with heparin-like oligosaccharides in heparan sulfate. Exp Parasitol 1997; 85:168-82.
15. Bell BA, Wood JF, Bansal R, et al. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 2009; 27:1448-53.
16. Dereeper A, Guignon V, Blanc G, et al. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res 2008; 36:W465-9.
17. Ancsin JB, Kisilevsky R. A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to hepatocytes. J Biol Chem 2004; 279:21824-32.
18. McCutchan TF, Lal AA, de la Cruz VF, et al. Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science 1985; 230:1381-3.
19. Cerami C, Kwakye-Berko F, Nussenzweig V. Binding of malarial circumsporozoite protein to sulfatides [Gal(3-SO4)beta 1-Cer] and cholesterol-3-sulfate and its dependence on disulfide bond formation between cysteines in region II. Mol Biochem Parasitol 1992; 54:1-12.
20. Suphavilai C, Looareesuwan S, Good MF. Analysis of circumsporozoite protein-specific immune responses following recent infection with Plasmodium vivax. Am J Trop Med Hyg 2004; 71:29-39.
21. Calvo-Calle JM, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro ZR, Nardin EH. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 1997; 159:1362-73.
22. Kebaier C, Voza T, Vanderberg J. Kinetics of mosquito-injected Plasmodium sporozoites in mice: fewer sporozoites are injected into sporozoite-immunized mice. PLoS Pathog 2009; 5:e1000399.
23. Chatterjee S, Wery M, Sharma P, Chauhan VS. A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Infect Immun 1995; 63:4375-81.
24. Rathore D, Nagarkatti R, Jani D, et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem 2005; 280:20524-9.
25. Coppi A, Natarajan R, Pradel G, et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey frommosquito tomammalian host. J ExpMed 2011; 208:341-56.
26. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 2005; 201:27-33.
27. Cerami C, Frevert U, Sinnis P, et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 1992; 70:1021-33.
28. Oliveira GA, Kumar KA, Calvo-Calle JM, et al. Class II-restricted protective immunity induced by malaria sporozoites. Infect Immun 2008; 76:1200-6.
29. Bejon P, Andrews L, Andersen RF, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005; 191:619-26.
30. Guinovart C, Aponte JJ, Sacarlal J, et al. Insights into long-lasting protection induced by RTS, S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS One 2009; 4:e5165.
31. Maire N, Aponte JJ, Ross A, et al. Modeling a field trial of the RTS, S/AS02A malaria vaccine. Am J Trop Med Hyg 2006; 75:104-10.